Miv Therapeutics, Inc. (IVT) Tops Q2 EPS by 117c; updates guidance

Miv Therapeutics, Inc. (NYSE: IVT) reported Q2 EPS of $1.23, $1.17 better than the analyst estimate of $0.06. Revenue for the quarter came in at $95.9 million versus the consensus estimate of $73.24 million.

GUIDANCE:

Miv Therapeutics, Inc. sees FY2025 EPS of $1.43-$1.49, versus the consensus of $0.33.

For earnings history and earnings-related data on Miv Therapeutics, Inc. (IVT) click here.

You May Also Be Interested In

• SpaceX: We are Go for Orbit
• Bessent taps Jefferies strategist David Zervos as adviser
• Nvidia’s AI dominance funds historic $150 billion buyback